The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases

Parakkal Deepak; Jordan E. Axelrad; Ashwin N. Ananthakrishnan

doi:10.1016/j.giec.2019.02.006

The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases

Parakkal Deepak, Jordan E. Axelrad, Ashwin N. Ananthakrishnan

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Crohn's disease and ulcerative colitis are chronic inflammatory diseases that lead to progressive bowel damage including the development of stricturing and penetrating complications. Increasingly, cross-sectional imaging with computed tomography or magnetic resonance scans have emerged as leading tools to: (1)assess disease activity; (2)monitor response to therapy or disease recurrence; and (3)identify disease-related complications. Several validated radiological scoring systems have been developed to quantify cross-sectional and longitudinal inflammatory burden in these diseases and to monitor response to treatment. Bowel ultrasound is also a simple and inexpensive tool but is operator dependent in its performance.

Original language	English
Pages (from-to)	447-470
Number of pages	24
Journal	Gastrointestinal Endoscopy Clinics of North America
Volume	29
Issue number	3
DOIs	https://doi.org/10.1016/j.giec.2019.02.006
State	Published - Jul 2019

Keywords

Abscess
CTE
Crohn's disease
Fistula
Inflammation
MRE
Strictures
Ulcerative colitis

Access to Document

10.1016/j.giec.2019.02.006

Cite this

@article{78056c8ba0c14836991ec0c911492d11,

title = "The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases",

abstract = "Crohn's disease and ulcerative colitis are chronic inflammatory diseases that lead to progressive bowel damage including the development of stricturing and penetrating complications. Increasingly, cross-sectional imaging with computed tomography or magnetic resonance scans have emerged as leading tools to: (1)assess disease activity; (2)monitor response to therapy or disease recurrence; and (3)identify disease-related complications. Several validated radiological scoring systems have been developed to quantify cross-sectional and longitudinal inflammatory burden in these diseases and to monitor response to treatment. Bowel ultrasound is also a simple and inexpensive tool but is operator dependent in its performance.",

keywords = "Abscess, CTE, Crohn's disease, Fistula, Inflammation, MRE, Strictures, Ulcerative colitis",

author = "Parakkal Deepak and Axelrad, {Jordan E.} and Ananthakrishnan, {Ashwin N.}",

note = "Funding Information: Disclosure statement: P. Deepak has received consulting fees from Janssen and Pfizer, Speaker fees from Abbvie, and has received research support from Takeda. A.N. Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, Gilead, and Merck, and has received research support from Pfizer. Funding Information: Disclosure statement: P. Deepak has received consulting fees from Janssen and Pfizer , Speaker fees from Abbvie , and has received research support from Takeda . A.N. Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, Gilead, and Merck, and has received research support from Pfizer. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = jul,

doi = "10.1016/j.giec.2019.02.006",

language = "English",

volume = "29",

pages = "447--470",

journal = "Gastrointestinal Endoscopy Clinics of North America",

issn = "1052-5157",

number = "3",

}

TY - JOUR

T1 - The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases

AU - Deepak, Parakkal

AU - Axelrad, Jordan E.

AU - Ananthakrishnan, Ashwin N.

N1 - Funding Information: Disclosure statement: P. Deepak has received consulting fees from Janssen and Pfizer, Speaker fees from Abbvie, and has received research support from Takeda. A.N. Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, Gilead, and Merck, and has received research support from Pfizer. Funding Information: Disclosure statement: P. Deepak has received consulting fees from Janssen and Pfizer , Speaker fees from Abbvie , and has received research support from Takeda . A.N. Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, Gilead, and Merck, and has received research support from Pfizer. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/7

Y1 - 2019/7

N2 - Crohn's disease and ulcerative colitis are chronic inflammatory diseases that lead to progressive bowel damage including the development of stricturing and penetrating complications. Increasingly, cross-sectional imaging with computed tomography or magnetic resonance scans have emerged as leading tools to: (1)assess disease activity; (2)monitor response to therapy or disease recurrence; and (3)identify disease-related complications. Several validated radiological scoring systems have been developed to quantify cross-sectional and longitudinal inflammatory burden in these diseases and to monitor response to treatment. Bowel ultrasound is also a simple and inexpensive tool but is operator dependent in its performance.

AB - Crohn's disease and ulcerative colitis are chronic inflammatory diseases that lead to progressive bowel damage including the development of stricturing and penetrating complications. Increasingly, cross-sectional imaging with computed tomography or magnetic resonance scans have emerged as leading tools to: (1)assess disease activity; (2)monitor response to therapy or disease recurrence; and (3)identify disease-related complications. Several validated radiological scoring systems have been developed to quantify cross-sectional and longitudinal inflammatory burden in these diseases and to monitor response to treatment. Bowel ultrasound is also a simple and inexpensive tool but is operator dependent in its performance.

KW - Abscess

KW - CTE

KW - Crohn's disease

KW - Fistula

KW - Inflammation

KW - MRE

KW - Strictures

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85063759755&partnerID=8YFLogxK

U2 - 10.1016/j.giec.2019.02.006

DO - 10.1016/j.giec.2019.02.006

M3 - Review article

C2 - 31078247

AN - SCOPUS:85063759755

SN - 1052-5157

VL - 29

SP - 447

EP - 470

JO - Gastrointestinal Endoscopy Clinics of North America

JF - Gastrointestinal Endoscopy Clinics of North America

IS - 3

ER -

The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this